U.K.’s NICE Consults On Value-Based Assessments, No Future For Value-Based Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s health technology assessment body intends to add disease burden and societal impact to appraisal criteria that allow a new drug to be cleared for prescribing in the National Health Service, although there are still concerns about end-of-life criteria no longer being taken into account.